This Congress Hub brings to you the latest updates from the European Academy of Dermatology and Venereology’s (EADV) Symposium series.

Infographic summarising the results from the Allegro-2b/3 trial which demonstrate clinician-reported efficacy, patient-reported improvement, and an acceptable safety profile with Litfulo treatment (a dual JAK3/TEC family kinase inhibitor) in adolescents with severe alopecia areata.

Article highlighting the key takeaways from the EADV 2023 Education Symposium on Atopic Dermatitis and Prurigo Nodularis.

It presents the impact of intense skin itching and recurrent lesions caused by inadequately controlled AD and PN, the role of specific interleukins in these two conditions, and the increasing evidence for the efficacy and safety profile of Dupixent in AD and PN.